<DOC>
	<DOCNO>NCT01143519</DOCNO>
	<brief_summary>Background : - Research show certain protein cell may link high risk develop inflammation , tumor , medical problem . By examine blood cell healthy volunteer respond environmental exposure , researcher hope good understand relationship gene , environmental factor , human disease . Objectives : - To examine specific gene protein blood cell respond environmental exposure . Eligibility : - Healthy volunteer 18 45 year age . Design : - The study involve one visit 45 60 minute . - Participants screen brief physical examination finger stick determine eligible donate blood study , complete questionnaire medication drug ( e.g. , cigarette ) may take . - Participants provide blood sample research purpose .</brief_summary>
	<brief_title>Study Effect SNPs p53 p53 Response Elements Inflammatory Response DNA Damage</brief_title>
	<detailed_description>This research study investigate role SNPs p53 p53 response element inflammatory response DNA damage . A total 200 participant age 18 year old carry one five SNPs interest wild-type control identify recruited Environmental Polymorphism Registry ( EPR ) . In addition , participant recruit base health outcome SNP association EPR registry study genotype-phenotype effect lymphocytes . The EPR long-term project collect store 15,000 DNA sample use research study individual great North Carolina Triangle Region . This observational gene association study recruit participant basis genotype phenotype observe lymphocyte response chemotherapeutic agent . The SNPs interest p53 , well four downstream target gene include FLT1 , MDM2 , TLR8 RRM1 . A maximum 150 mLs blood obtain participant one visit last approximately one hour . Cells donate blood sample examine response expose environmental stress ex vivo . The primary objective determine association five SNPs p53 target gene expression exposure Nutlin doxorubicin ( chemotherapeutic agent ) outcome measure RT-PCR . The five SNPs p53 rs1042522 , MDM2 rs2279744 , FLT1 C-677T , TLR8 rs3761624 RMM1 rs1465952 . The secondary objective : ( 1 ) determine p53 promoter occupancy measure ChIP analysis follow SNPs : FLT1 C-677T , TLR8 rs3761624 RMM1 rs1465952 ; ( 2 ) measure apoptosis Annexin V-PI assay p53 rs1042522 SNPs ; ( 3 ) examine cell cycle profile analysis ( FACS ) cytofluorometry p53 rs1042522SNPs ; ( 4 ) determine DNA repair use Pulse Field Electrophoresis Gel ( TAFE gel ) follow p53 rs1042522SNPs . Furthermore , association SNPs interest phenotypic characteristic explore use EPR health exposure survey identify significant genotype-phenotype association EPR population . The effect association test lymphocyte function exposure Nutlin doxorubicin . We hope result study lead discovery important information regard role SNPs locate p53 p53 response elements human disease , potentially identify new target future study .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>INCLUSION CRITERIA : Male female 18 year age old Participants must able understand provide write informed consent participate study Participants must able travel CRU Healthy participant define International Red Cross guideline ( Healthy mean individual feel well perform normal activity . If individual chronic condition diabetes high blood pressure , healthy also mean treated condition control ) . Participants health outcome identify genotypephenotype association study . EXCLUSION CRITERIA : Use immunosuppressant immunemodifying drug [ e.g. , Rituxan , Humira , Enbrel , Cyclosporin ( Neoral , Sandimmune , SangCya ) , Azathioprine ( Imuran ) ] , Monoclonal antibodies [ e.g. , infliximab ( Remicade ) ] , Corticosteroids ( e.g. , prednisone , prednisolone dexamethasone ) History treat cancer chemotherapy radiation ( healthy control ) Confirmed suspect immunosuppressive immunodeficient condition Body weight &lt; 50 kg ( &lt; 110 lb ) Temperature &gt; 37.6 C ; blood pressure &lt; 90/50 mm Hg blood pressure &gt; 160/100 mm Hg ; pulse rate &lt; 50 &gt; 100 beats/minute Participants carry SNPs TLR8 FLT1 currently take hormonal contraception ( e.g . oral contraceptive , IUDs hormone , contraceptive patch ) hormone replacement therapy exclude study unless participant hormone treatment 1 month longer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2, 2016</verification_date>
	<keyword>p53</keyword>
	<keyword>Inflammatory Response</keyword>
	<keyword>Gene Association</keyword>
	<keyword>Nutlin</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>